Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US EPA grants three more years of fenamiphos use

The US EPA has allowed a further three years for the use of existing stocks of Bayer CropScience's nematicide, Nemacur (fenamiphos). Use was due to end on October 6th 2014, but this has been extended to October 6th 2017 following a request from the Golf Course Superintendents Association of America (GCSAA). Bayer voluntarily cancelled fenamiphos registrations in 2007. Sale and distribution by persons other than the registrant were allowed until October 5th 2012 under an extended phase-out in 2011. The GCSAA told the EPA that golf course owners had purchased a ten-year supply of fenamiphos in 2008 because of the lack of alternatives for nematode control on turf. The EPA says that it was unaware of the volume of stocks in the hands of golf course owners when it extended the phase out in 2011. It believes that it is more cost effective to allow use of the stocks rather than "transporting hazardous substances over potentially lengthy distances to a pesticide disposal facility".

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG002595

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel